SURVANTA 8ML VIAL

Beractant Injection, a natural lung surfactant, primarily works by reducing surface tension in the alveoli of premature infants' lungs. It is composed of a mixture of phospholipids, neutral lipids, and surfactant-associated proteins, mimicking the composition of endogenous pulmonary surfactant. When administered, beractant spreads across the air-liquid interface in the alveoli, forming a phospholipid monolayer. This monolayer reduces the work of breathing by lowering surface tension, preventing alveolar collapse, and facilitating gas exchange. The surfactant proteins in beractant play a crucial role in maintaining the stability and function of the phospholipid layer, modulating inflammation, and providing host defense against pathogens in the respiratory system. By replenishing deficient or dysfunctional endogenous surfactant, beractant injection helps to establish and maintain lung function in premature infants with respiratory distress syndrome (RDS), enabling proper respiration and promoting alveolar stability.

Beractant

Surfactant.

Injection

The following are the uses of Beractant Injection:

• Used for treating Respiratory Distress Syndrome (RDS) in premature infants
• Used for improving lung function and reducing the need for mechanical ventilation
• Used for preventing or reducing the severity of lung injury in preterm babies
• Used for enhancing lung maturation and reducing surface tension in the lungs
• Used for supporting the development of stable breathing in premature infants
• Used for reducing the risk of long-term respiratory complications
• Used for promoting better oxygenation and gas exchange in premature lungs
• Used for improving survival rates and overall respiratory outcomes in RDS cases

In the case of an overdose of Beractant Injection, the primary concern is the potential for respiratory distress. Overdosing may lead to increased respiratory secretions, causing breathing difficulties and requiring immediate medical intervention. Symptoms of overdose can include rapid breathing, wheezing, and increased mucus production. Medical professionals should closely monitor vital signs and provide supportive care to manage these symptoms effectively. Prompt treatment is crucial to prevent severe respiratory complications.

In the case of a missed dose of Beractant Injection, it is important to act quickly. If you realize you have missed a dose, administer the medication as soon as possible, even if the next scheduled dose is approaching. Do not double the dose to make up for the missed one, as this may increase the risk of side effects. It is recommended to contact your healthcare provider for specific guidance if you miss a dose, especially if it happens frequently, as they may need to adjust your dosing schedule or provide further instructions.

To administer Beractant Injection, ensure the vial is at room temperature, gently swirl the vial to dissolve any particles, draw the medication into a syringe, and inject it into the trachea or endotracheal tube under the guidance of a healthcare professional, following the prescribed dosage and administration technique provided by your doctor.

Following are the conditions/situations when Beractant Injection should not be used:

• Must not be used in premature infants with known allergies to any component of the medication, especially to Beractant.
• Not suitable for infants with severe respiratory distress syndrome (RDS) who have already developed established pulmonary air leak syndromes such as pneumothorax or pulmonary interstitial emphysema.
• Contraindicated in infants with severe pulmonary hemorrhage.
• Should be avoided in infants with known or suspected severe air leak syndromes.
• Not recommended for use in infants with active infections or sepsis.
• Discontinue use if the infant shows signs of anaphylactoid reaction or severe adverse reactions.

The side effects of Beractant Injection may include:

• Fast or irregular breathing
• Slow heart rate
• Fever
• Apnea (temporary cessation of breathing)
• Bradycardia (abnormally slow heart rate)
• Hypotension (low blood pressure)
• Bradygastria (slowed gastric emptying)
• Pallor (pale skin)

Following are the precautions and warnings for Beractant Injection:

• Beractant Injection should only be administered by trained healthcare professionals in a clinical setting equipped to manage respiratory distress and other potential complications.
• Not recommended for infants with known allergies to any of its components, including beractant, cow-lung surfactant extract, or egg phospholipids.
• Caution is advised in premature infants, as the risk of complications may be higher due to their immature respiratory systems.
• It is essential to monitor vital signs and respiratory status closely during and after the administration of the injection.
• The injection should be inspected visually for any particulate matter or discoloration before use, and any vials with abnormalities should be discarded.
• Avoid rapid infusion as it may lead to adverse cardiovascular effects; administer the injection slowly as directed.
• Ensure the correct dosage is administered based on the infant's weight and clinical condition to minimize the risk of side effects.
• The long-term effects of Beractant Injection are not fully established, so follow-up monitoring of treated infants is recommended.

Following are the drug interactions for Beractant Injection:

• Concomitant use with exogenous surfactants or other respiratory medications may lead to reduced effectiveness of Beractant, as it may interfere with lung function.
• Beractant can interact with other medications administered intratracheally, potentially affecting their distribution and absorption.
• The use of Beractant with mechanical ventilation may require adjustments in ventilator settings to ensure optimal respiratory support.
• Corticosteroids, often used in preterm infants, can influence the effectiveness of Beractant, and close monitoring is necessary.
• Antibiotics administered concurrently may have altered pharmacokinetics due to Beractant's impact on lung physiology.
• Drug interactions with other medications that affect blood pressure or heart rate may be possible, requiring careful monitoring.
• Caution is advised when using Beractant with medications that affect blood clotting, as it may influence coagulation parameters.

Following are the food interactions for Beractant Injection:

• Beractant should be used with caution in preterm infants receiving parenteral lipid emulsions as it may increase the risk of hyperlipidemia. Monitor lipid levels closely.
• Ensure adequate nutritional support, especially in preterm infants, as Beractant is not a replacement for proper nutrition.
• No specific food interactions are reported, but maintaining a balanced diet is essential for overall health.
• Avoid grapefruit and grapefruit juice, as they may impact the absorption of certain medications, although no direct interaction with Beractant is noted.
• Alcohol consumption is not recommended, especially in infants, as it can have adverse effects on their health and development.
• Breastmilk or formula feeding should continue as directed by healthcare professionals.
• Always consult healthcare providers for specific dietary recommendations and adjustments during Beractant therapy.

Beractant Injection should be stored in a controlled environment, specifically at a temperature range of 2°C to 8°C (36°F to 46°F) in a refrigerator. It is crucial to keep the injection in its original packaging to maintain its integrity and protect it from light. Do not freeze the medication as it may affect its potency. Once the vial is opened, it should be used immediately and any unused portion discarded to ensure sterility. Proper disposal of Beractant Injection is essential; do not dispose of it in regular household waste or pour it down the drain. Contact your healthcare provider or pharmacist for guidance on safe disposal methods to minimize environmental impact. Keep this medication out of the reach of children to prevent accidental exposure.

Following are the quick tips for Beractant Injection:

• Administer the injection under medical supervision only.
• Ensure the injection is stored at the appropriate temperature as directed by the pharmacist.
• Verify the expiration date before use and discard if expired.
• Use a sterile syringe and needle for each injection to prevent contamination.
• Inject at a 90-degree angle into the muscle or as instructed by your healthcare provider.
• Do not reuse or share needles to prevent infection.
• Inform your doctor immediately if you experience any adverse reactions.